Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Sci. Signal., 16 October 2012
Vol. 5, Issue 246, p. pe46
The Response of Cancers to BRAF Inhibition Underscores the Importance of Cancer Systems Biology
Edward C. Stites*
Clinical Translational Research Division, The Translational Genomics Research Institute, Phoenix, AZ 85004, USA.
Present address: Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110, USA.
The BRAF inhibitor vemurafenib has become an important treatment option for melanoma patients, the majority of whom have a BRAF(V600E) mutation driving their malignancy. However, this same agent does not generally benefit colon cancer patients who have the BRAF(V600E) mutation. Recent work suggests that BRAF(V600E) inhibition by vemurafenib results in decreased negative feedback to the epidermal growth factor receptor (EGFR) pathway and that the different clinical responses are due to differences in the amount of EGFR present in these two cancers. The experimental work that identified the feedback signaling was an elegant mix of functional genomic approaches and focused, hypothesis-driven cellular and molecular biology. The results of these studies suggest that combined treatment of BRAF(V600E)-driven colon cancers with both vemurafenib and EGFR inhibitors is worth clinical evaluation.
Friedegund Meier and Annalisa M. VanHook (29 January 2013) Sci. Signal.6 (260), pc3.
[DOI: 10.1126/scisignal.2003968] |Abstract »|Full Text »|Podcast »
Daniela Beck, Heike Niessner, Keiran S. M. Smalley, Keith Flaherty, Kim H. T. Paraiso, Christian Busch, Tobias Sinnberg, Sophie Vasseur, Juan Lucio Iovanna, Stefan Drießen, Björn Stork, Sebastian Wesselborg, Martin Schaller, Tilo Biedermann, Jürgen Bauer, Konstantinos Lasithiotakis, Benjamin Weide, Jürgen Eberle, Birgit Schittek, Dirk Schadendorf, Claus Garbe, Dagmar Kulms, and Friedegund Meier (29 January 2013) Sci. Signal.6 (260), ra7.
[DOI: 10.1126/scisignal.2003057] |Editor's Summary »|Abstract »|Full Text »|PDF »|Supplementary Materials »
Michael B. Yaffe and Nancy R. Gough (1 January 2013) Sci. Signal.6 (256), eg1.
[DOI: 10.1126/scisignal.2003881] |Abstract »|Full Text »|PDF »